LoadingLoadingLoadingThe quick read
Latest quote
Net selling: insiders sold $2.6M and bought $0 on the open market in 90 days (SEC Form 4). Congress: net selling of $3K to $3K in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNet selling: insiders sold $2.6M and bought $0 of ICHR stock on the open market in the 90 days to Oct 18, 2026, according to SEC Form 4 filings. $2.6M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was MacKenzie, Iain (Director), who sold $1.7M. The latest filing was on Oct 5, 2026.
Rep. Debbie Wasserman Schultz (D) sold $3K to $3K on Jun 17, 2026, disclosed 27 days later. In total, 1 member disclosed 1 ICHR trade with trade dates in the last 180 days, filed a median 27 days after trading.
This summary uses filings available on Oct 18, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position and insiders have been net selling.
Buys/Adds (1)
AQR
$16.3M
added
Sells/Trims (2)
D.E. Shaw
$2.8M
trimmed
Bank of America
$2.5M
trimmed
Sells (1)
$3K
sold
No tracked top-trader positions in ICHR right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Aug 3, 2026
Period ending
Jun 30, 2026
Earnings per share
$0.21 expected
Revenue
No reported revenue on record
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 3, 2026 | $0.22 / $0.21Alpha Vantage | +4.76% beat | Unavailable | Unavailable |
| Mar 31, 2026 | May 4, 2026 | $0.15 / $0.13Alpha Vantage | +15.38% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Feb 9, 2026 | $0.01 / -$0.06Alpha Vantage | +$0.07 beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 3, 2025 | $0.07 / $0.12Alpha Vantage | -41.67% miss | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 4, 2025 | Unavailable | - | Unavailable | Unavailable |
| Mar 31, 2025 | May 5, 2025 | $0.12 / $0.26Alpha Vantage | -53.85% miss | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 4, 2025 | $0.08 / $0.11Alpha Vantage | -27.27% miss | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 4, 2024 | $0.12 / $0.11Alpha Vantage | +9.09% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $239.3M | $223.6M | $256.1M | $294.8M |
| Cost of what it sold | $211.2M | $202.6M | $226.3M | $253.8M |
| Gross profit | $28.1M | $21.0M | $29.8M | $41.0M |
| What it spent | ||||
| Research and development | $5.9M | $5.6M | $5.5M | $7.8M |
| Sales and admin | $22.5M | $27.1M | $22.6M | $24.1M |
| Other operating costs | $19.1M | $2.1M | -$1.1M | $1.9M |
| Total operating expenses | $47.6M | $34.8M | $27.0M | $33.8M |
| What was left | ||||
| Operating profit | -$19.4M | -$13.8M | $2.7M | $7.2M |
| Interest on debt | $1.7M | $1.7M | $1.7M | $1.5M |
| Profit before tax | -$22.2M | -$15.8M | $84.0K | $5.4M |
| Tax | $683.0K | $132.0K | $2.6M | $4.4M |
| Net profit | -$22.9M | -$16.0M | -$2.5M | $998.0K |
| EBITDA | -$13.6M | -$4.1M | $9.4M | $14.1M |
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
0 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
